Oestrogen receptors in colorectal carcinoma


Abstract

The oestrogen receptor content of colorectal adenocarcinoma was investigated using an established ligand binding biochemical assay and two more recently introduced techniques using specific monoclonal antibodies (Abbott ER-EIA and ER-ICA assay kits). Twenty nine tumours were investigated by the ligand binding assay. Only one (3.4%) tumour gave a weakly positive result (11 fmol/mg cytosol protein); the rest were all negative. Where sufficient tissue was available, the receptors were also determined by a quantitative immunoassay in 18 patients and an immunohistochemical method in 13 patients. The results were similarly all negative.

It is concluded that most colorectal carcinomas, irrespective of sex, are oestrogen receptor negative, and it is thus unlikely that hormonal manipulation would have an influence on the course of the disease.

The association between breast cancer and other extra-mammary neoplasms, particularly colorectal carcinoma, is well established. This, coupled with the presence of some similar epidemiological features in the two tumours, suggest that there may be a common aetiological factor. In this context some investigators have recently reported the presence of oestrogen receptors in up to 30% of colorectal carcinomas, and the possibility that these tumours may be influenced by appropriate endocrine manipulation has been raised. The scientific literature, however, also contains reports of studies which failed to show the presence of oestrogen receptors in colorectal cancer.

This discrepancy, together with the recent introduction of monoclonal antibodies that can be used for assessing the oestrogen receptor content of tumours by quantitative enzyme immunoassay, as well as immunohistological staining of tissue sections, has prompted us to investigate the presence of oestrogen receptors in 29 colorectal carcinomas using a standard ligand binding assay and to validate the results using these other techniques.

Methods

Tumour tissue from 29 patients with adenocarcinoma of the colon and rectum was studied (12 men, 17 women, mean age 66.2 (SD 12.8) years). Two patients (one male, one female) only had recurrent tumour tissue available for study. A representative piece of tumour was selected by PMD immediately after removal of the specimen at operation. The tissue was immediately immersed in liquid nitrogen and the receptor content of each tumour measured by a ligand binding assay. Where sufficient tissue was available, receptors were also determined by a quantitative enzyme immunoassay and an immunohistochemical technique (see below).

LIGAND BINDING ASSAY

Oestrogen and progesterone receptors were measured by a method conforming to the guidelines recommended by the EORTC Breast Cancer Cooperative Group. Briefly, biopsy specimens were pulvred frozen by a microdissemembrator (Braun Instruments; FT Scientific Instruments Ltd, Brendan, Gloucestershire). A crude cytosol was prepared by mixing the tissue powder with phosphate buffer (0.01 M NaH2PO4, 1.5 mM EDTA, 30 mM NaCl, 10 mM monothioglycerol, 30% v/v glycerol, pH 7.4; tissue weight:buffer volume = 1:8) and centrifuging at 2000 × g for 20 minutes. Two hundred microlitre aliquots of crude cytosol were incubated with seven different concentrations of 3H-E2 (oestrogen receptors) or 3H-Org 2058 (progesterone receptors) ranging between 0.5 and 5 × 10-8 M. Non-specific binding was determined by incubating with a 200-fold excess of diethylstilboestrol (oestrogen receptors) or Org-2058 (progesterone receptors).

After incubation overnight at 4°C unbound steroid was removed with dextran coated charcoal (final concentrations, 0.25% Norit A and 0.025% dextran T70). Scatchard plot analysis was performed to calculate the concentration of receptor binding sites (fmol/mg protein) and the equilibrium dissociation constant (Kd). The lower limit of sensitivity of this method is about 10 fmol/mg.

QUANTITATIVE ENZYME IMMUNOASSAY

Eighteen specimens were examined by this method using the Abbott ER-EIA monoclonal antibody kit for the quantitative measurement of oestrogen receptor content. In this method beads coated with rat monoclonal anti-oestrogen receptor are incubated with specimens (tissue cytosols prepared as above), or the appropriate standards, or control. During incubation, oestrogen receptors bind to the solid phase. Unbound materials are removed by aspiration and washing. Bound
oestrogen receptor is labelled by incubating with a second antibody conjugated with horseradish peroxidase. After washing, the beads are incubated with enzyme substrate solution (H₂O₂ and ortho-Phenylenediamine-HCl) to develop a colour which is a measure of bound oestrogen receptor conjugate. The intensity of the colour is read using a spectrophotometer set at 492 nm. A standard curve is obtained plotting the oestrogen receptor concentration of the standard versus the absorbance. The oestrogen receptor concentrations of the specimens and the controls can be determined by interpolation.

### Immunohistochemistry
Thirteen cases were examined by this method using the Abbott ER-ICA monoclonal antibody kit. Frozen sections, 5 µm thick, from tumour tissue which had been stored in liquid nitrogen were thawed mounted on to slides. Sections were immediately fixed in formaldehyde-phosphate buffered saline for 10 minutes, rinsed in phosphate buffered saline, followed by further fixation in cold methanol for five minutes and cold acetone for three minutes.

<table>
<thead>
<tr>
<th>Site</th>
<th>No (%\textsubscript{g})</th>
<th>Operation</th>
<th>No (%\textsubscript{g})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caecum</td>
<td>5 (17.2)</td>
<td>Right hemicolectomy</td>
<td>10 (34.5)</td>
</tr>
<tr>
<td>Ascending</td>
<td>3 (10.3)</td>
<td>Left hemicolectomy</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>Transverse</td>
<td>3 (10.3)</td>
<td>Sigmoid colectomy</td>
<td>8 (27.6)</td>
</tr>
<tr>
<td>Descending</td>
<td>2 (6.9)</td>
<td>Anterior resection</td>
<td>6 (20.7)</td>
</tr>
<tr>
<td>Sigmoid</td>
<td>9 (31.0)</td>
<td>Anteriposterior excision</td>
<td>2 (6.9)</td>
</tr>
<tr>
<td>Rectum</td>
<td>7 (24.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dukes' staging and differentiation</th>
<th>No (%\textsubscript{g})</th>
<th>Differentiation</th>
<th>No (%\textsubscript{g})</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>3 (10.3)</td>
<td>Well</td>
<td>1 (3.4)</td>
</tr>
<tr>
<td>B</td>
<td>12 (41.4)</td>
<td>Moderate</td>
<td>20 (68.9)</td>
</tr>
<tr>
<td>C</td>
<td>10 (34.5)</td>
<td>Poor</td>
<td>8 (27.6)</td>
</tr>
<tr>
<td>D</td>
<td>4 (13.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results
The sites of carcinoma, operations performed, Dukes' staging and differentiation are shown in table 1. The results of the three receptor assays are shown in table 2. Of the 29 tumours examined by the ligand binding assay, only one patient (3.4%) had detectable oestrogen receptor content (11 fmol/mg cytosol protein). This tumour was also rich in low affinity progesterone receptors (116 fmol/mg cytosol protein). The lesion was a recurrent caecal carcinoma in a 43 year old woman which had invaded the urogenital tracts. None of the remaining primary tumour specimens showed specific high affinity oestrogen or progesterone receptors by the ligand binding technique. All 18 cases examined with the solid phase oestrogen immunoassay and all 13 cases examined with the immunohistological technique were oestrogen receptor negative (table 2). These cases did not include the weakly positive case detected by the ligand binding assay.

### Discussion
Our findings strongly suggest that most colorectal adenocarcinomas are oestrogen receptor negative, irrespective of the patient's sex, site of tumour or its degree of differentiation. The very low oestrogen receptor content detected in the only positive case in this study is probably of no practical importance. Of the 29 cases examined, 18 were studied with two different techniques, and 13 by three different techniques. All methods gave identical results. They are all established methods in which well characterised reagents and appropriate controls are used, and which are successfully used for the determination of oestrogen receptor content in breast tumours. These results are consistent with those of some published reports but not with others. The cause of this discrepancy is not obvious. It has been suggested that the surgical technique and the time interval during which the tumour was resected may be important.
Oestrogen receptors in colorectal carcinoma

is subjected to ischaemia before it is immersed in liquid nitrogen may influence the results of receptor assays. In this study the tumours were immersed in liquid nitrogen as soon as they were removed, in exactly the same way as breast tumours are dealt with in this hospital, without any deleterious effect on their oestrogen receptor content. It is therefore unlikely that the brief period of ischaemia to which the tumours are inevitably subjected would have any clinically important effect on oestrogen receptor concentrations unless these were extremely low to start with.

Another possible source for the discrepancies noted in published oestrogen receptor assay results could be the histological types of tumours examined. In the breast associations have been found between certain histological types of carcinoma and their oestrogen receptor content. All our colorectal tumours were of the usual adenocarcinoma type. None was of the much less common pure mucinous or of the rare signet ring adenocarcinoma type, and the oestrogen receptor content of these uncommon varieties may therefore be different.

Another possibility is that the specific epitopes recognised by the monoclonal antibodies used in two of the assays are not present in the oestrogen receptor of colorectal carcinomas as these monoclonal antibodies are produced specifically for the detection of oestrogen receptor in breast and female genital tract tissue. This seems unlikely as the same two monoclonal antibodies have been reported to be used for the demonstration of oestrogen receptor content in gastric adenocarcinoma.

The ligand binding assay has also been used successfully for the demonstration of oestrogen receptor in other tissues, such as stomach and prostate, as well as in one of our colonic tumours (case 22).

It is concluded that most colorectal adenocarcinomas of the usual type, in both sexes, are oestrogen receptor negative, although an occasional case may show unimportant concentrations of the receptor protein. It therefore seems unlikely that endocrine manipulations would have an influence on the course of these tumours.

We thank Mrs Gillian C Miller for her valuable technical assistance. This study was partly funded by the Peel Medical Research Trust.

4 Francavilla A, DiLeo LA, Conte PD. Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding non-cancerous colon tissue. Gastroenterology 1987;93:1301-6.
9 Scatchard G. The attraction of proteins for small molecules and ions. Am NY Acad Sci 1949;41:660-72.
Oestrogen receptors in colorectal carcinoma.

P M Dawson, S Shousha, S D Blair, G D Carter, J Jones, J Alaghband-Zadeh and N A Theodorou

J Clin Pathol 1990 43: 149-151
doi: 10.1136/jcp.43.2.149

Updated information and services can be found at:
http://jcp.bmj.com/content/43/2/149

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/